Metoprolosuccinat Dura

Metoprolol, the active ingredient in Metoprolosuccinat Dura, is a beta blocker presented as an oral tablet for oral use. It selectively blocks β1‑adrenergic receptors, thereby reducing heart rate and myocardial contractility, and is indicated for hypertension, angina pectoris, post‑myocardial infarction care, and chronic heart failure in adult patients.

GNH USA supplies Metoprolosuccinat Dura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets.

Metoprolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

Hypertension: lowers blood pressure by reducing cardiac output and renin release. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. Post‑myocardial infarction: improves survival and reduces risk of recurrent events. Chronic heart failure: enhances left ventricular function and reduces hospitalization.

Metoprolol may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: feeling of tiredness. - Dizziness: light‑headedness on standing. - Bradycardia: slower heart rate. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dangerously low. - Heart block: impaired cardiac conduction. - Hypotension: markedly low blood pressure. - Bronchospasm: airway narrowing, especially in asthma.

When prescribing Metoprolol, clinicians should consider several precautionary measures to ensure safe use.

- Assess cardiovascular status: evaluate heart rate and blood pressure before initiation. - Review respiratory history: avoid in patients with active bronchospastic disease. - Monitor for diabetes: may mask hypoglycemia symptoms. - Adjust in renal/hepatic impairment: dose may need modification. - Caution in elderly: increased sensitivity to hypotension and bradycardia. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Metoprolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective beta blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia and AV block. - Antidiabetic agents (insulin, sulfonylureas): may enhance hypoglycemia unawareness.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase plasma levels of metoprolol. - NSAIDs: can reduce antihypertensive effect. - Antithyroid drugs: may diminish metoprolol’s heart‑rate control.